INO.US Inovio Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
1.43 USD
Close of Nov 15, 2026
0.5600 2.72
Market cap
USD 268M
P/E
-
P/B
37.18x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INO.US undervalued?

Graham number

The Graham number of Inovio Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inovio Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Inovio Pharmaceuticals Inc yet.

Inovio Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate…

Full company profile